Kornimate/medical-research-clean huggingface dataset:
imaging studies in corticobasal syndrome

Conditions: Cortico Basal Degeneration; Corticobasal Syndrome; Corticobasal Syndrome(CBS); Corticobasal Degeneration; Corticobasal Degeneration (CBD); Corticobasal Syndrome (CBS)

Summary: the primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. the investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

corticobasal syndrome (cbs) is a neurodegenerative disorder characterized by cognitive and behavioral change, as well as asymmetric parkinsonism, dystonia, myoclonus, and limb apraxia. emerging evidence suggests neuroinflammation plays a key role in the pathogenesis of neurodegenerative disease, including the 4r tauopathies and ad, and neuroinflammation has been linked mechanistically to damage of the white matter. the primary goal of this study is to investigate inflammation and white matter damage using imaging and blood samples. the investigator's will use the pet ligand 11c-er176 to assess patterns of neuroinflammation in the brain and neurite orientation dispersion and density imaging (noddi) to measure white matter microstructure, including axonal density and alignment. the investigator's will also investigate blood plasma metrics, including neurofilament light chain and plasma glial fibrillary acidic protein (gfap) that measure neuroaxonal injury and astrogliosis, and inflammation and tau metrics. the investigator's will employ beta-amyloid (a) and tau (t) pet to subdivide the cbs patients into those with biomarker ad (a+t+, cbs-ad) and those without biomarker ad (cbs-4r). the investigator's will also compare these groups to disease controls with typical amnestic biomarker ad (amn-ad) and healthy controls (hc) that have previously been recruited for other grants (existing data collected under approved irbs).

Eligibility criteria:
inclusion criteria: * age 18 years or older * meet possible or probable cbs criteria exclusion criteria: * subjects will be excluded if mri is contraindicated (due to implanted device, severe claustrophobia, etc) * subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the cbs syndrome * subjects will be excluded if they have a mutation in the progranulin gene * subjects will excluded if they have received anti-aβ therapy * women who are pregnant will be excluded * subjects will be excluded if they are actively taking daily anti-inflammatory medications (nsaids, corticosteriods, etc) * subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid/glucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning

Keywords: neurodegeneration neurodegenerative disease cbs cbd corticobasal syndrome corticobasal degeneration
the individualized behavioral intervention of smartphone app in the treatment of type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: the patients with type 2 diabetes who underwent routine hypoglycemic agents and insulin therapy were evaluated for 48 weeks with maltose software.

this study enrolled 400 patients with type 2 diabetes in five centers in shandong province, china. patients with type 2 diabetes who met the inclusion / exclusion criteria were randomly assigned to the trial group (conventional treatment + maltose app) or the control group (conventional treatment) in a 1: 1 ratio. the control group: given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere. the trial group: the patients were treated with conventional hypoglycemic drugs. the treatment plan was decided by the researcher according to the patient's condition. the intervention was not done in this study. interventions include: 1. weekly diabetes-related science articles. 2. patients reported hypoglycemia or other adverse reactions, the competent physician to deal with. 3. questionnaires published out the hospital (2 weeks 1), the feedback for the problem. 4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online. 5. personalize the development of diet, exercise program. 6. different insulin and oral hypoglycemic drug medication time to remind. 7. hypoglycemic drug side effects query.

Eligibility criteria:
inclusion criteria: 1. male and female patients diagnosed with type 2 diabetes, age ≥ 18 years and ≤ 65 years; 2. diagnosis of type 2 diabetes ≥6 months; 3. the patient signed an informed consent form and agreed to collect the data. the trial group agreed to apply the maltose app during the trial period to study popular science articles, to receive software reminders and to answer questions regularly; 4. hba1c≥7.0% in the last one (≤3 months) before enrollment; 5. be able to use mobile app; 6. the mobile phone used by the patient must support maltose app installation. 7. receiving regular diabetes education in the hospital. exclusion criteria: 1. has participated in any randomized controlled clinical study; 2. to long-term use of insulin pump as the main treatment of type 2 diabetes; 3. patients with type 1 diabetes; 4. pregnant or lactating women; 5. doctor, alcohol, drug abuse, schizophrenia, severe vision and hearing impaired; 6. can not accept software manager; 7. other investigators considered it inappropriate to participate in the study.
feasibility study of the solo™ insulin pump

Conditions: Type 1 Diabetes; Insulin Pump Users

Summary: the purpose of this study is to assess the safety and usability of the solo™ insulin micropump in subjects with type 1 diabetes who are pump users.

this is a multi center, one arm, open label and prospective study to assess the safety and usability of the solo™ micropump insulin delivery system . the study will include a 30 days treatment period with the solo micropump with no special care required for maintaining glycemic control and with an optional extension period of up to six month. the study will consist of up to 5 visits and one follow up phone call one week after termination of the study. in case of participating the extension period, additional visits will consist once a month. visit 1 includes eligibility, baseline evaluation and training in handling of the solo™ system. if no additional practice is required patients will be enrolled. visit 2 will commence and solo pump will be filled with insulin. if additional practice is required subject will be sent home for an additional training period of a few days practice using saline and then return for visit 2. treatment visits will take place at 3, 14 and 30 days after the enrolment. additional visits will take place at 60, 90 and 180 days depending on the extension period. subjects will be asked to record blood glucose measurements, daily activities and carbohydrate consumptions between visits. seven days after termination of study treatment a telephone contact with the study subject will take place for the purpose of adverse event reporting and the completion of dtsq questionnaire. measurements that will be used for assessing the safety of the device are glucose levels and any occurrence of ae's. subjects will complete dtsq and performance questionnaires before and at the end of the treatment period for usability evaluation. blood and urine tests will be taken at visit 1 and 5, vital signs and physical examination will be evaluated at all study visits.

Eligibility criteria:
inclusion criteria: * age range of: * 18 to 60 years in israel * 16 to 60 years in austria * type i diabetes and pump treatment duration of more than 6 months. * subjects who are using humalog®, novorapid®, and apidra® 100u/ml insulin * measures glucose at least four times per day. * no more than one severe hypoglycemic or ketoacidosis episode within one year * willing to sign an informed consent. * cooperative, willing to attend all study visits. exclusion criteria: * a1c \>= 10.0% * two or more documented events of severe hypoglycemia within the previous 12 months * diabetes related hospitalization over the past 12 months * current significant diabetes-related complications * pregnant, lactating or planning to become pregnant during the course of the study * substance or alcohol abuse * uncontrolled hypertension * known dermal hypersensitivity to medical adhesive * recurrent episodes of skin infections or dermatological allergies * serious or unstable medical or psychological conditions * current participation in other clinical studies. * working for a competitor company

Keywords: insulin pumps diabetes
joint stiffness following knee replacement surgery

Conditions: Joint Contracture

Summary: our primary research question is to find out whether there is a genetic component to the development of joint contractures following knee surgery, through the application of lab techniques.

after total knee replacement surgery, some people develop joint stiffness, which is also called a joint contracture. contractures cause the envelope of the knee (called the capsule) to stiffen and become rigid so the patient can no longer move their knee the way they used to. after stretching and other exercises, only a surgery can try and divide or remove the contracture. the main purpose of this research is to study the cause of the contracture and specifically if certain people are predisposed to contractures.

Eligibility criteria:
inclusion criteria: -knee contractures post arthroplasty scheduled for arthrotomy with debridement of capsular tissue controls will be patients scheduled for arthrotomy with debridement of capsular tissue for the other reasons(primary knee arthroplasty, orif of the knee secondary to trauma, acl repair, amputation, elective joint arthroplasty with capsuloplasty etc.) exclusion: * transmissible disease (hiv, hep b,c) * confirmed or suspected neoplasia * suspected infection

Keywords: joint contracture total knee arthroplasty
relationship between fgf19 overexpression and disease prognosis

Conditions: Hepatocellular Carcinoma (HCC)

Summary: a real-world study of fgf19 overexpression status and treatment outcome and prognosis in advanced hepatocellular carcinoma

this is a real-world, single-arm, observational study to collect information on the diagnosis and prognosis of hepatocellular carcinoma patients with previous tissue samples in routine clinical practice, and to detect the expression of fgf19 expression in tissue samples, with a view to discovering prognostic and predictive markers for advanced hepatocellular carcinoma the treatment protocol of this study follows the clinical practice and does not set any limitations on the interventions for patients. in this study, real-world liver tissue samples will be collected from patients with hepatocellular liver cancer after surgical resection, and the samples will be sent to a third-party pathology slice reviewer for review, and a report on the fgf19 expression results will be returned to the project team. simultaneously collect clinical data of the patient. according to the principle of clinical routine diagnosis and treatment, the patient's imaging data were collected, and the imaging of the 2-month period was evaluated, and whether the disease progressed was judged according to the rescist v1.1 standard. every two months will be an observation cycle. each subject will be followed from the first treatment until disease progression or change of drug regimen.

Eligibility criteria:
inclusion criteria: * age ≥18 years on the day of signing the informed consent form * histologically or clinically confirmed diagnosis of intermediate to advanced hcc * adequate tissue samples of previous liver cancer * expected survival of more than 3 months exclusion criteria: * fibrous laminae or sarcomatoid hcc or mixed hcc-icc, or other rare non-hcc pathologic subtypes * other conditions that, in the opinion of the investigator, make participation in this trial inappropriate

Keywords: fgf19 hepatocellular carcinoma hcc
effect of coaching on surgeon well-being, job satisfaction, & fulfillment

Conditions: Professional Burnout; Professional Stress; Job Stress

Summary: researchers are trying to determine if individualized professional coaching improves physicians' sense of well-being and job satisfaction.


Eligibility criteria:
inclusion criteria: * surgeons at mayo clinic exclusion criteria: * retired surgeons at mayo clinic; physicians in other disciplines or organizations
vascular effects of hesperidin in metabolic syndrome

Conditions: Endothelial Dysfunction; Metabolic Syndrome

Summary: it has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (dm2) and cardiovascular diseases (cvd). consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. while molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.


Eligibility criteria:
inclusion criteria: * metabolic syndrome (atpiii criteria) * bmi \<35 * age 20-55 exclusion criteria: * history of cancer. * history of cardiovascular diseases. * any other acute or chronic illness which requires administration of steroids or other drugs able to interfere with glucose or lipid metabolism.

Keywords: endothelial metabolic syndrome hesperidin
using explainable ai risk predictions to nudge influenza vaccine uptake

Conditions: Influenza; Vaccination; Health Promotion; Health Behavior; Risk Reduction

Summary: the study team previously demonstrated that patients are more likely to receive flu vaccine after learning that they are at high risk for flu complications. building on this past work, the present study will explore whether providing reasons that patients are considered high risk for flu complications (a) further increases the likelihood they will receive flu vaccine and (b) decreases the likelihood that they receive diagnoses of flu and/or flu-like symptoms in the ensuing flu season. it will also examine whether informing patients that their high-risk status was determined by analyzing their medical records or by an artificial intelligence (ai) / machine-learning (ml) algorithm analyzing their medical records will affect the likelihood of receiving the flu vaccine or diagnoses of flu and/or flu-like symptoms.

geisinger has partnered with medial earlysign and developed an ml algorithm to identify patients at risk for serious (moderate to severe) flu-associated complications on the basis of their existing electronic health record (ehr) data. geisinger will apply this algorithm to current patients during the 2021-22 flu season. this study will evaluate the effect of contacting patients identified as high risk with special messages to encourage vaccination. these communications will inform patients they are at high risk with either (a) no additional explanation, (b) an explanation that this determination comes from an analysis of their medical records, along with a short list of the top factors from their medical record that explain their risk, and (c) the additional explanation that an ai or ml algorithm made this determination, along with a short list of the top factors from their medical record that explain their risk. included in the study will be current geisinger patients 18+ years of age with no contraindications for flu vaccine and who have been assessed by the medial algorithm and assigned a risk score. the primary study outcomes will be the rates of flu vaccination and flu diagnosis during the 2020-21 season by targeted patients.

Eligibility criteria:
inclusion criteria: * aged 18 or older * current geisinger patient at the time of study * falls in the top 10% of patients at highest risk, as identified by the flu-complication risk scores of machine learning algorithm (which operates on coded ehr data) exclusion criteria: * has contraindications for flu vaccination * has opted out of receiving communications from geisinger via all of the modalities being tested

Keywords: flu vaccine choice architecture machine learning perceived credibility personalized risk factors flu complications
determine the effect on cognitive impairment measures by providing hearing-assistance to skilled nursing facility residents

Conditions: Hearing Impairment

Summary: the purpose of the study is to see if a commercially available hearing assistance device called the pocketalker has an effect on performance on cognitive (memory and thinking) tests among skilled nursing facility residents. investigators are asking residents to perform cognitive tests with and without hearing assistance equipment known as pocketalkers. this study will be conducted at one urban skilled nursing facility (snf) with the goal of understanding the extent to which hearing impairment impacts commonly used cognitive impairment measures for clinical assessment. cognitive performance will be measured, cerumen occlusion, and perceived hearing.


Eligibility criteria:
inclusion criteria: * admitted to unit of intervention * ability to communicate and follow simple commands * capacity to consent assessed with standard questions used to assess capacity or having a surrogate who can provide consent. exclusion criteria: * not on the unit of intervention * obtunded or comatose state * inability to communicate verbally * inability to consent and without surrogate * non-english speaking
waitlist controlled comparison of cognitive-behavioral vs. mindfulness-based online-treatments for women with low sexual desire

Conditions: Hypoactive Sexual Desire Disorder

Summary: problems with sexual function are common and distressing. the most frequent sexual difficulty in women is a lack of sexual desire with a prevalence of 20-30%. when low sexual desire is experienced over several months and causes significant personal distress, a sexual dysfunction can be diagnosed (icd-10: hypoactive sexual desire disorder: hsdd). a distressing lack of desire is reported by 6% of sexually active women. psychological interventions are the treatment of choice for women with hsdd. promising treatment approaches include cognitive-behavioral and mindfulness-based interventions. a recent meta-analysis also showed that internet-delivered programs are a valid alternative to face-to-face treatments. aim of this project to assess the effectivity of two eight-week online-programs consisting of cognitive-behavioral (cope) and mindfulness-based (mind) interventions for women with hsdd. both treatments will be compared to a waitlist-control group. for this project, two well-established group-treatment manuals will be translated into german and adapted to a multimedia online-environment. all participants will be guided through the programs by well-qualified ecoaches.


Eligibility criteria:
inclusion criteria: * 18 years or older * female gender * able to read, write and speak german * meet criteria of icd-10 criteria of hypoactive sexual desire disorder (established via online-screening and telephone interview) * experience significant sexuality-related personal distress (established via online-screening and telephone interview) exclusion criteria: * currently pregnant * ongoing medical or psychological treatment for low desire or other sexual dysfunctions or plans to enter such treatment (e.g., in-person sexual therapy, couples therapy) during study participation * suicide ideation (established via telephone interview) * currently experiencing significant symptoms of a mental disorder that might interfere with study participation (e.g., eating disorders, obsessive-compulsive disorder, posttraumatic stress disorder, major depression, bipolar disorder) as established via telephone interview * currently experiencing significant symptoms of a physical condition that might interfere with study participation (e.g., cancer, multiple sclerosis) as established via telephone interview * current substance-abuse disorder * current or lifetime psychotic disorder * significant relationship discord or violence

Keywords: sexual dysfunction female sexual interest/arousal disorder internet-based intervention mindfulness cognitive-behavioral therapy
treatment of patients with newly onset of type 1 diabetes with mesenchymal stem cells

Conditions: Type 1 Diabetes

Summary: the main hypothesis of the investigators study is that the development of autoimmune diabetes may be halted att diagnosis by the immune modulatory properties of mesenchymal stem cells.


Eligibility criteria:
inclusion criteria: * ability to provide written informed consent * mentally stable and able to comply with the procedures of the study protocol * clinical history compatible with type 1 diabetes diagnosed less than 10 days of enrolment stimulate c-peptide \>0.1 nmol/l exclusion criteria: * patients with bmi\>30 * patients with unstable cardiovascular status * patients with active infections, unless treatment is not judged necessary by the investigators * patients with serological evidence of infection with hiv, hepatitis b or hepatitis c. * sexually active females who are not a) postmenopausal, b) surgically sterile or c) using an acceptable method of contraception: oral contraceptives, norplant, depo-provera and barrier devices combined with spermicidal gel are acceptable. * patients with known or previous malignancy. patient with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with autologous msc.

Keywords: type 1 diabetes mesenchymal stem cells intervention
colombia epidemiologic surveillance study

Conditions: Pneumonia; Meningitis; Bacteremia; Sepsis

Summary: the study will determine the reduction in invasive pneumococcal disease (ipd) after the introduction of a national immunization program with pcv-7 in bogota. the original leap study determine incidence of ipd prior to introduction of pcv-7 in brazil, costa rica and colombia. leap ii is the continuation of the study in colombia only.

the study was stopped based on a decision to include pcv 10 in the national immunization program in colombia. the study was designed to measure the impact of pcv 7 and 13 and is no longer feasible.

Eligibility criteria:
inclusion criteria: * children 28 days to 36 months of age * presenting to a participating facility with a measured temperature of 39 degrees c or higher within 24 hours prior to screening, or with clinical suspicion of pneumonia, meningitis, bacteremia, sepsis, or other invasive pneumococcal disease exclusion criteria: * any patient hat based on the clinical impression of the treating physician should not participate in the study: examples such as those with suspected dengue or urinary tract infection

Keywords: epidemiology surveillance streptococcal pneumonia